Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1298

—

eaa6686c-8dd9-58a7-bbb2-495f905341c8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.478
  • INTERFERON_ALPHA_RESPONSE+0.453
  • INTERFERON_GAMMA_RESPONSE+0.396
  • INFLAMMATORY_RESPONSE+0.299
  • IL6_JAK_STAT3_SIGNALING+0.285
  • APICAL_SURFACE+0.284
  • E2F_TARGETS+0.277
  • HEDGEHOG_SIGNALING+0.277
  • G2M_CHECKPOINT+0.274
  • NOTCH_SIGNALING+0.254

Top 10 suppressed

  • MYC_TARGETS_V2-0.238
  • BILE_ACID_METABOLISM-0.208
  • HEME_METABOLISM-0.204
  • MYC_TARGETS_V1-0.189
  • GLYCOLYSIS-0.164
  • OXIDATIVE_PHOSPHORYLATION-0.157
  • UNFOLDED_PROTEIN_RESPONSE-0.151
  • DNA_REPAIR-0.139
  • ADIPOGENESIS-0.138
  • HYPOXIA-0.134

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0388
medullo-epn-umap@date-based
MedMedulloblastoma0.791
2TCGA-GV-A3QG-01A-11R-A220-07
bladder-landscape@3
——0.775
3DRR168533
bladder-landscape@3
——0.770
4SRR8518418
breast-umap@18
—D0.769
54ff81b7f-2dbc-453f-a68b-fe40315b2ef7
melanoma-umap@29
——0.769
6SRR8518429
breast-umap@18
—D0.766
7s0122149
melanoma-umap@29
——0.763
8MDT-AP-2874
medullo-epn-umap@date-based
MedMedulloblastoma0.753
9SRR6013527
lung-landscapes@6
—cohortMD20.752
10SRR650191
bladder-landscape@3
——0.750

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.478Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.453Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.396Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.299Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.285Inavolisib— uncovered
APICAL_SURFACE0.284Temsirolimus— uncovered
E2F_TARGETS0.277Inavolisib— uncovered
HEDGEHOG_SIGNALING0.277Inavolisib— uncovered
G2M_CHECKPOINT0.274Inavolisib— uncovered
NOTCH_SIGNALING0.254Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.244Inavolisib— uncovered
KRAS_SIGNALING_UP0.239Inavolisib— uncovered
IL2_STAT5_SIGNALING0.214Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.190Remibrutinib— uncovered
ANGIOGENESIS0.170Remibrutinib— uncovered
COMPLEMENT0.163Inavolisib— uncovered
MYOGENESIS0.146Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.103Inavolisib— uncovered
ANDROGEN_RESPONSE0.100Inavolisib— uncovered
PANCREAS_BETA_CELLS0.096Cobimetinib— uncovered